Version July 2025
Tinea corporis (ringworm): Children and Adolescents: Topical: Cream 1%: Apply to affected and surrounding area(s) twice daily until clinical resolution; typically 2 weeks.
Tinea cruris (jock itch): Children and Adolescents: Topical: Cream 1%: Apply to affected and surrounding area(s) once daily until clinical resolution; typically 2 weeks.
Tinea pedis (athlete's foot): Children and Adolescents: Topical: Cream 1%: Apply to affected and surrounding area(s) once daily until clinical resolution; typically 4 weeks.
Tinea versicolor (pityriasis versicolor): Children and Adolescents: Topical: Cream 1%: Apply to affected and surrounding area(s) once daily for 2 weeks.
There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely necessary due to low systemic absorption.
There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely necessary due to low systemic absorption.
(For additional information see "Oxiconazole: Drug information")
Tinea infection:
Tinea corporis/tinea cruris: Topical: Cream 1%, lotion 1%: Apply to affected and surrounding area(s) 1 to 2 times daily until clinical resolution, typically 1 to 3 weeks (Ref).
Tinea pedis (labeled use)/tinea manuum (off-label use): Topical: Cream 1%, lotion 1%: Apply to affected and surrounding area(s) 1 to 2 times daily until 1 week after clinical resolution, typically for 4 weeks total (Ref).
Tinea versicolor (pityriasis versicolor): Topical: Cream 1%: Apply to affected area(s) and immediate surrounding skin once daily for 2 weeks.
There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely due to low systemic absorption.
There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely due to low systemic absorption.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
1% to 10%: Dermatologic: Burning sensation of skin (≤1%), pruritus (≤2%)
<1%: Dermatologic: Allergic contact dermatitis, cutaneous nodule, desquamation, dyshidrotic eczema, erythema of skin, folliculitis, maceration of the skin, papule of skin, skin fissure, skin irritation, skin pain, skin rash, stinging of the skin, tingling of skin
Hypersensitivity to oxiconazole or any component of the formulation
Concerns related to adverse effects:
• Irritation: Discontinue if sensitivity or irritation occurs
Other warnings/precautions:
• Appropriate use: For topical use only; not for ophthalmologic, oral, or vaginal use.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Cream, External:
Oxistat: 1% (30 g [DSC], 60 g [DSC], 90 g [DSC]) [contains benzoic acid, cetyl alcohol, propylene glycol]
Generic: 1% (30 g, 60 g, 90 g)
Lotion, External:
Oxistat: 1% (30 mL, 60 mL) [contains benzoic acid, cetyl alcohol, propylene glycol]
May be product dependent
Cream (Oxiconazole Nitrate External)
1% (per gram): $10.40
Lotion (Oxistat External)
1% (per mL): $28.05
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Topical: For external use only; avoid contact with eyes, nose, mouth, or other mucous membranes. Apply to the affected and immediate surrounding area(s). Avoid occlusive dressings unless otherwise directed. Wash hands before and after use.
For external use only; avoid contact with eyes, nose, mouth, or other mucous membranes. Avoid occlusive dressings unless otherwise directed. Wash hands before and after use.
Cream: Store at 15°C to 30°C (59°F to 86°F).
Lotion: Store at 20°C to 25°C (68°F to 77°F); excursion permitted to 15°C to 30°C (59°F to 86°F). Shake well before use.
Cream: Treatment of tinea pedis, tinea cruris, and tinea corporis; treatment of tinea (pityriasis) versicolor (FDA approved in pediatric patients [age not specified] and adults).
Lotion: Treatment of tinea pedis, tinea cruris, and tinea corporis (FDA approved in adults).
None known.
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program
There are no known significant interactions.
When administered orally, teratogenic effects were not observed in animal reproduction studies.
Monitor for application site reactions.
The cytoplasmic membrane integrity of fungi is destroyed by oxiconazole which exerts a fungicidal activity through inhibition of ergosterol synthesis. Effective for treatment of tinea pedis, tinea cruris, tinea corporis, and tinea versicolor (pityriasis versicolor). Active against Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton violaceum, Microsporum canis, Microsporum audouinii, Microsporum gypseum, Epidermophyton floccosum, Candida albicans, and Malassezia furfur.
Absorption: In each layer of the dermis; very little systemically after one topical dose
Distribution: To each layer of the dermis
Excretion: Urine (<0.3%)
